Oroflurb (Flurbiprofen)

Flurbiprofen blocks the cyclo‑oxygenase enzymes COX‑1 and COX‑2, which are essential for converting arachidonic acid into prostaglandins. By limiting prostaglandin synthesis, the drug reduces inflammation, pain signals, and fever, providing therapeutic relief in inflammatory and painful disorders.

The specific dose of Oroflurb is determined by the prescribing healthcare professional based on the patient’s condition, age, renal and hepatic function, and other individual factors. Prescribers set the appropriate strength, frequency, and duration according to clinical guidelines.

Flurbiprofen, like other NSAIDs, is generally avoided during the third trimester of pregnancy because it may affect fetal cardiovascular function. Use during pregnancy or lactation should only occur if the potential benefit outweighs the risk, and it must be decided by a qualified healthcare provider.

To request Oroflurb, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Oroflurb (flurbiprofen) offers potent analgesic and anti‑inflammatory effects comparable to ibuprofen or naproxen, but it may have a slightly higher risk of gastrointestinal irritation. Choice of NSAID depends on individual patient tolerance, comorbidities, and physician preference, with flurbiprofen often selected for moderate‑to‑severe pain where rapid onset is desired.

Oroflurb should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and sources of heat to maintain stability and potency throughout its shelf life.

Oroflurb is taken orally, usually with a full glass of water. It may be taken with or without food, although taking it with meals can reduce gastrointestinal discomfort. Patients should follow the dosing schedule prescribed by their healthcare professional.

The most serious risks include gastrointestinal ulceration or bleeding, severe renal impairment, hepatic injury, life‑threatening skin reactions such as Stevens‑Johnson syndrome, and increased cardiovascular events like myocardial infarction or stroke. Prompt medical attention is required if any of these symptoms appear.

Oroflurb should be avoided in individuals with known hypersensitivity to flurbiprofen or any NSAID, active gastrointestinal ulcer or bleeding, severe heart failure, uncontrolled hypertension, and in the third trimester of pregnancy. It is also contraindicated in patients with severe renal or hepatic impairment unless specifically directed by a physician.